Literature DB >> 9463684

The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue.

N Jirakanjanakit1, T Sanohsomneing, S Yoksan, N Bhamarapravati.   

Abstract

A micro-focus reduction neutralization test (mFRNT) was evaluated as an alternative test to the ordinary plaque reduction neutralization test (PRNT) for the determination of dengue virus and Japanese encephalitis virus neutralizing antibody responses in persons receiving dengue vaccine. The 2 tests were similar in terms of titres and ability to detect seroconversion. Although the neutralizing antibody titres obtained by mFRNT were slightly lower than those given by PRNT, the differences were less than two-fold, indicating than mFRNT was reliable. Reproducibility of mFRNT was confirmed by 10 replicate tests using the same control serum. Therefore, mFRNT may be useful in large-scale investigations of neutralizing antibody levels, for example, in young children forming part of an immunization programme; it can be performed quickly and is economical, requiring only a small volume of sera.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463684     DOI: 10.1016/s0035-9203(97)90050-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  12 in total

1.  Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.

Authors:  Lidong Liu; Kun Wen; Jie Li; Dongmei Hu; Yanfen Huang; Liwen Qiu; Jianpiao Cai; Xiaoyan Che
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

2.  Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies.

Authors:  J Groen; P Koraka; J Velzing; C Copra; A D Osterhaus
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

3.  An in-depth analysis of original antigenic sin in dengue virus infection.

Authors:  Claire M Midgley; Martha Bajwa-Joseph; Sirijitt Vasanawathana; Wannee Limpitikul; Bridget Wills; Aleksandra Flanagan; Emily Waiyaiya; Hai Bac Tran; Alison E Cowper; Pojchong Chotiyarnwong; Pojchong Chotiyarnwon; Jonathan M Grimes; Sutee Yoksan; Prida Malasit; Cameron P Simmons; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

4.  Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Authors:  Claire M Midgley; Aleksandra Flanagan; Hai Bac Tran; Wanwisa Dejnirattisai; Kriangkrai Chawansuntati; Amonrat Jumnainsong; Wiyada Wongwiwat; Thaneeya Duangchinda; Juthathip Mongkolsapaya; Jonathan M Grimes; Gavin R Screaton
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

5.  Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.

Authors:  Abigail Culshaw; Kristin Ladell; Stephanie Gras; James E McLaren; Kelly L Miners; Carine Farenc; Heleen van den Heuvel; Emma Gostick; Wanwisa Dejnirattisai; Apirath Wangteeraprasert; Thaneeya Duangchinda; Pojchong Chotiyarnwong; Wannee Limpitikul; Sirijitt Vasanawathana; Prida Malasit; Tao Dong; Jamie Rossjohn; Juthathip Mongkolsapaya; David A Price; Gavin R Screaton
Journal:  Nat Immunol       Date:  2017-09-25       Impact factor: 25.606

6.  Cross-reacting antibodies enhance dengue virus infection in humans.

Authors:  Wanwisa Dejnirattisai; Amonrat Jumnainsong; Naruthai Onsirisakul; Patricia Fitton; Sirijitt Vasanawathana; Wannee Limpitikul; Chunya Puttikhunt; Carolyn Edwards; Thaneeya Duangchinda; Sunpetchuda Supasa; Kriangkrai Chawansuntati; Prida Malasit; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  Science       Date:  2010-05-07       Impact factor: 47.728

7.  Adaptor Protein 1A Facilitates Dengue Virus Replication.

Authors:  Umpa Yasamut; Nopprarat Tongmuang; Pa-thai Yenchitsomanus; Mutita Junking; Sansanee Noisakran; Chunya Puttikhunt; Justin Jang Hann Chu; Thawornchai Limjindaporn
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

8.  SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation.

Authors:  Gopinathan Pillai Sreekanth; Aporn Chuncharunee; Aunchalee Sirimontaporn; Jutatip Panaampon; Sansanee Noisakran; Pa-Thai Yenchitsomanus; Thawornchai Limjindaporn
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

9.  Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.

Authors:  Tatyana M Timiryasova; Matthew I Bonaparte; Ping Luo; Rebecca Zedar; Branda T Hu; Stephen W Hildreth
Journal:  Am J Trop Med Hyg       Date:  2013-03-04       Impact factor: 2.345

10.  Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development.

Authors:  Henrik Salje; Isabel Rodríguez-Barraquer; Kaitlin Rainwater-Lovett; Ananda Nisalak; Butsaya Thaisomboonsuk; Stephen J Thomas; Stefan Fernandez; Richard G Jarman; In-Kyu Yoon; Derek A T Cummings
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.